JC09 Rec'd PCT/PTO Q2 AUG 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : C.J.M. MEADE, et al. U.S. Appln. No. : Not Yet Assigned Confirmation No. : Not Yet Assigned U.S. Filing Date : Not Yet Assigned Title of Invention : NEW PHARMACEUTIC ANTICHOLINERGICS AN Attny. Docket No. : 1/1457 PCT		
Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450		
August 2, 2005		
TRANSMITTAL LETTER FOR INFOR	RMATION DISCI	LOSURE STATEMENT
Sir:		
Transmitted herewith concerning the subject ap Statement (Form 1449A/B) under 37 C.F.R. §§ hereinbelow.		
1.97(b). This Statement is being date of a national application other than a conti §1.53 (d); ii) within three (3) months of the dat 37 C.F.R. §1.491 in an international application on the merits; or iv) before the mailing of a first continued examination under 37 C.F.R. §1.114	inued prosecution a te of entry of the na n; iii) before the m st Office action after	ational stage as set forth in ailing of a first Office action
1.97(c). This Statement is being C.F.R. §1.97(b), but before the mailing date of notice of allowance under 37 C.F.R. §1.311, or in the application. This Statement is being acc	: i) a final action un : iii) an action that	nder 37 C.F.R. §1.113, ii) a
A statement as specified in 37 (C.F.R. §1.97(e) [se	e below]; or
The fee set forth in 37 C.F.R. §	l.17(p).	

The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(c) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. §1.17(p).
1.97(e).
Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or
No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.
The fee set forth in 37 C.F.R. §1.17(p).
The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
1.704(d). Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.

10/544235 JC09 Rec'd PCT/PTO 02 AUG 2005,

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Andrea D. Small

Attorney for Applicant(s)

Reg. No. 54,859

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4816 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on August 2, 2005.

Andrea D. Small, Reg. No. 44,859

10/544235

JC09 Rec'd PCT/PT0 0 2 TASE OF A SERVING Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Substitute for form 1449A/PTO		respond to a collection of information unless it contains a valid OMB control number Complete if Known			
00.	Substitute for form 1449/01 TO		Application Number	Not Yet Assigned		
IN	FORMATION DISC	CLC	SURE	Filing Date	Not Yet Assigned	
	TATEMENT BY AF			First Named Inventor	Christopher J. M. MEADE	
0	TATEMENT BY A	• -	i OAITI	Art Unit	Not Yet Assigned	
	(Use as many sheets as ne	essary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	1/1457 PCT	

U. S. PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
***************************************		^{US-} 2002/0193394	12-19-2002	Bernd DISSE					
		^{US-} 2004/039011	02-26-2004	Bernd DISSE					
		^{US-} 2001/021381	09-13-2001	George TREACY					
		^{US-} 2002/119152	08-29-2002	George TREACY					
		^{US-} 2003/220361	11-27-2003	Thomas Victor MAGEE, et al.					
		^{US-} 2003/220366	11-27-2003	Thomas Victor MAGEE, et al.					
	***************************************	US-							
***************************************		US-							
		US-							
	***************************************	US-							
		US-							
		US-							
		US-							
***************************************		US-							
***************************************		US-							
		US-							
***************************************		US-							
		US-							

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ 'Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶			
		WO 02/072095	09-19-2002	Boehringer Ingelheim Pharma KG					
	İ	WO 00/51637	09-08-2000	CENTOCOR Inc.	>				
		WO 03/068233	08-21-2003	PFIZER, Inc.	***************************************				
	Ī				, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
	<u> </u>								

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for for	rm 1449B/PTO				Complete if Known		
				Application Number	Not Yet Assigned		
INFORI	NATION I	DISCLO	SURE	Filing Date	Not Yet Assigned		
STATEMENT BY APPLICANT				First Named Inventor	Christopher J. M. MEADE		
				Art Unit	Not Yet Assigned		
(U	se as many sheets	as necessary)		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	1/1457 PCT		

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
		HANSEL, T.T., et al. "Tiotropium Bromide: A Novel Once-Daily Anticholinergic Bronchodilator for the Treatment of COPD" Drugs of Today, Vol. 38, No. 9, 2002, pgs 585-600	٠				
		BARNES, P.J., "New Treatments for COPD", Nature Reviews, Drug Discovery, Nature Publishing Group, Vol. 1, No. 6, 2002, pgs 437-446	********				
,	•	SAADEH, C.K., et al. "Infliximab Therapy for Rheumatoid Arthritis (RA) Induced Significant Control of Asthma in Patients with both RA and Asthma or Asthma/COPD in Addition to Improving RA Status" J. Allergy and Clinical Immun. vol. 109, no. 1, 2002, pg S243					
		BABU, K., et al. "Soluble Tumor Necrosis Factor Alpha (TNF-ALPHA) Receptor (Enbrel) as an Effective Therapeutic Strategy in Chronic Severe Asthma", J. Allergy and Clinical Immun. Vol. 111, No. 2, 2003, pg S277					

<u> </u>							

Examiner		Date	
Signature		 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy or this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.